Global Advisory Committee Identifies Solutions for Addressing Top Lupus Barriers The Addressing Lupus Pillars for Health Advancement (ALPHA) project is a unique global consensus initiative that seeks to identify and prioritize the fundamental barriers or knowledge gaps that will allow providers, researchers and scientists to improve diagnosis, treatment and systems of care for people with…
DetailsMore great news for people with lupus! The U.S. Food and Drug Administration (FDA) has approved Lupkynis™ (voclosporin) to treat lupus nephritis (lupus-related kidney disease) in adults when used in combination with a background immunosuppressive therapy regimen. Lupkynis is the second new therapy authorized to treat this potentially life-threatening complication of lupus. Developed by Aurinia…
DetailsGSK’s Benlysta® (belimumab) is First Lupus Nephritis Treatment Approved by FDA The U.S. Food and Drug Administration (FDA) in late December 2020 approved Benlysta® to treat lupus nephritis (lupus-related kidney disease) in adults. The decision makes Benlysta the first lupus therapy authorized to treat this potentially life-threatening complication of the disease. Another milestone, this new…
DetailsPhase 3 Trial Finds Benlysta Significantly Improves Kidney Response in People with Lupus Nephritis UPDATE 16/09/2020 In new results on the international phase 3 clinical trial (BLISS-LN) of the drug Benlysta (belimumab), researchers found that Benlysta reduced the risk of worsening kidney function during the study by almost 50%, compared with standard therapy alone. The…
DetailsAccess to Hydroxychloroquine for People with Lupus The Lupus Association of NSW is aware of the potential use of hydroxychloroquine and chloroquine for the treatment of coronavirus (COVID-19). This means that some people with Lupus who use hydroxychloroquine to manage their condition are having difficulty accessing this medication. Hydroxychloroquine, a medication taken by approximately 90% of…
DetailsNew restrictions on prescribing hydroxychloroquine for COVID-19 The following is an extract from the TGA website of this alert: 24 March 2020 In recent days there has been considerable focus on the potential for hydroxychloroquine and the similar compound chloroquine (which is not marketed in Australia) to help in treating COVID-19. Hydroxychloroquine is used…
DetailsCOVID-19 & Access to Hydroxychloroquine At present the trials are ongoing and there isn’t sufficient evidence to conclude whether it will be effective. Science Magazine stated that the available evidence that chloroquine and hydroxychloroquine work against COVID-19 was ‘thin’. The U.S. Society of Critical Care Medicine said “there is insufficient evidence to issue a recommendation…
DetailsInternational Lupus Community Reaches First-Ever Agreement on Barriers to Research, Drug Development, Care and Access Findings from a study published in Lupus Science & Medicine™ provide an actionable framework to advance the lupus field, which has seen many failed clinical trials, variations in care and poor access to care worldwide. The study, “Global Consensus Building…
DetailsWorld Lupus Federation issues global report for World Lupus Day highlighting the life-altering effects of lupus and the challenges people with lupus face every day. WASHINGTON, May 9, 2017 /PRNewswire-USNewswire/ — Almost half (43%) of people living with lupus responding to a recent poll* indicated that they worry the most about physical inactivity and social isolation…
DetailsResearchers face multiple obstacles that can hinder their ability to show whether a potential lupus treatment works or may be better than a current treatment. Years of disappointing results in lupus drug development demonstrates that a different approach is needed. In 2009, the Lupus Foundation of America established the LFA Collective Data Analysis Initiative (LFA…
Details
